Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Most COVID-19 drug trials reported race and ethnicity, but participation varied. Researchers must address factors limiting minority involvement in clinical trials to ensure equitable data.
Area Of Science
- Clinical Trials
- Health Disparities
- COVID-19 Research
Background
- Racial and ethnic minorities experienced disproportionate COVID-19 hospitalization and death.
- Understanding demographic representation in clinical trials is crucial for equitable research.
- COVID-19 drug randomized controlled trials (RCTs) are key to evaluating effective treatments.
Purpose Of The Study
- To assess the frequency of reported race and ethnicity in COVID-19 drug RCTs.
- To examine how race and ethnicity reporting correlates with trial characteristics.
- To identify trends in participation across different racial and ethnic groups.
Main Methods
- Scoping review of RCTs for approved COVID-19 drugs (remdesivir, baricitinib, molnupiravir).
- Searches conducted across major databases (PubMed, Cochrane) and preprint servers (Jan 2020-May 2022).
- Data extraction included demographic variables (race, ethnicity), study design, and participant outcomes.
Main Results
- 17 RCTs (17,935 participants) were included; 76% reported race/ethnicity and were US-based, industry-funded.
- Asian, Black, Latinx, and White participants were most common in remdesivir trials.
- Outcome assessment varied by race/ethnicity: Native American/Hawaiian in ventilation trials, Black/White in recovery trials, Asian/Latinx/multirace in hospitalization/death trials.
Conclusions
- While most trials reported demographics, participation varied significantly across racial and ethnic groups.
- Study-level factors in COVID-19 drug RCTs may influence minority participation.
- Future research should focus on increasing minority representation to inform equitable interventions.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...